Verici Dx plc (LON:VRCI – Get Free Report) traded up 11.1% during trading on Tuesday . The stock traded as high as GBX 0.30 and last traded at GBX 0.25. Approximately 8,366,714 shares were traded during trading, an increase of 363% from the average daily volume of 1,806,996 shares. The stock had previously closed at GBX 0.23.
Verici Dx Stock Performance
The company has a quick ratio of 8.49, a current ratio of 3.94 and a debt-to-equity ratio of 3.03. The company has a 50 day simple moving average of GBX 0.34 and a 200-day simple moving average of GBX 0.47. The stock has a market capitalization of £5.72 million, a price-to-earnings ratio of -0.28 and a beta of 1.26.
Verici Dx Company Profile
Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
Further Reading
- Five stocks we like better than Verici Dx
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Verici Dx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verici Dx and related companies with MarketBeat.com's FREE daily email newsletter.
